Bristol-Myers Squibb Company: Business Overview, Financials & Competitive Analysis
Bristol-Myers Squibb Company scores 7/10 on the AskCyborg Cyborg Score (Strong). Bristol-Myers Squibb's growth portfolio now offsets legacy declines with management consistently under-promising and over-delivering, setting up strong risk/reward. Bristol-Myers Squibb is upgraded to Buy as its growth portfolio now offsets legacy declines, validating a bullish contrarian thesis. Patent cliffs for Eliquis and Opdivo loom in 2028, but a robust.
What is Bristol-Myers Squibb Company's industry? Bristol-Myers Squibb Company (bms.com) operates in Biopharmaceuticals. AskCyborg classifies Bristol-Myers Squibb Company under Biopharmaceuticals in its company registry.
Bristol-Myers Squibb is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for atrial fibrillation (28% of 2024 revenues), ni...
Cyborg Score thesis
Bristol-Myers Squibb's growth portfolio now offsets legacy declines with management consistently under-promising and...
Read the full analyst-debate transcript →Get the Latest Bristol-Myers Squibb Company Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeBristol-Myers Squibb Company Overview
Pro stress-test →Bristol-Myers Squibb is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for atrial fibrillation (28% of 2024 revenues), nivolumab (Opdivo) for cancer treatment (19% of 2024 revenues), and lenalidomide (Revlimid) for multiple myeloma (12% of 2024 revenues). BMS is undergoing a strategic transformation with its growth portfolio offsetting legacy product declines.
Strategic Profile
Pro stress-test →A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol-Myers Squibb's growth portfolio revenue rose 15% in Q4 and 17% for the full year, nearly offsetting a $4 billion decline in legacy products. 2026 will be a data-rich year with over 10 pivotal readouts and six potential new product launches, positioning the company for long-term growth.
Competitive Landscape
Pro stress-test →One of Bristol-Myers Squibb's 26 competitors is Eli Lilly, a Corporation company based in Indianapolis, IN. BMS competes in oncology, immunology, cardiovascular, and cell therapy markets against major pharma peers including Pfizer, Merck, and Johnson & Johnson. Eliquis and Opdivo remain the heavy hitters, yet the market's patience is wearing thin as Bristol must prove its newer products can genuinely support the business as the legacy portfolio declines.
Industry Context
Bristol-Myers Squibb Company operates in Biopharmaceuticals.
Key facts
Founded: 1887 · Headquarters: Princeton, New Jersey, US · Revenue: $48.2B · Market cap: $114B